Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This study found that olorofim demonstrated potent in vitro and in vivo antifungal activity against dermatophytes, resolving skin lesions in a guinea pig model similar to clotrimazole, suggesting it may be a promising treatment for dermatophytosis.

This study found that povidone iodine, thiabendazole ointment, captan ointment, and Burroughs Wellcome Ringworm Ointment were effective against Trichophyton equinum var. autotrophicum in horses, but large-scale use may be limited by practicality and cost.

This study found that oral cyclosporine combination therapy led to new hair growth in 71% of patients with severe and refractory alopecia areata, though mild and transient side effects were common.

This study found that oral cyclosporine therapy was more effective than betamethasone mini-pulse therapy for treating alopecia areata, with a better patient-reported outcome on hair regrowth, despite a higher incidence of mild, reversible adverse effects in the cyclosporine group.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.

This study observed that thymol from Origanum marjoram essential oil significantly promoted hair regrowth and reduced inflammation in cyclophosphamide-induced alopecia in rabbits, with effects that were comparable to or exceeded those of betamethasone, highlighting its potential as a safer treatment alternative.

This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

Lowering the dose of cyclosporin caused hair loss that didn't improve even when the dose was increased again.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

Oral cyclosporin doesn't stop hair loss.

This study concluded that 0.05% betamethasone dipropionate cream is more effective than other topical treatments for improving alopecia areata over 12 weeks.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This study found that cyclophosphamide-induced hair follicle damage in C3H mice could be remodelled into intact anagen hair follicles with topical cyclosporin A, especially in anagen IV stage follicles.

This case report describes successful treatment of a 21-year-old patient with lichen planopilaris using keratolytic lotions, a combination of corticosteroids, salicylic acid, and tacrolimus cream, which stopped disease progression.

This study reported that using piroctone olamine in either a shampoo or leave-on product form significantly increased hair retention and improved scalp condition in women with perceived hair thinning.

This report describes two renal transplant patients whose hair loss improved after switching from tacrolimus to cyclosporine, suggesting that cyclosporine might counteract steroid-induced alopecia.

This study reviewed the genetic and phenotypic aspects of Olmsted syndrome, highlighting pathogenic mutations in TRPV3 and MBTPS2 genes and their association with specific skin manifestations like symmetrical keratoderma and hyperkeratotic plaques.

In this study, cyclosporin was found to prolong the hair-existing phase in nude mice, while corticosteroids inhibited its effect and suppressed hair regrowth.

In this study, 1% pimekrolimus cream was found to be more effective than 0.05% clobetasol propionate for treating active plaques in patients with alopecia areata.

This study found that both an anti-dandruff shampoo containing piroctone olamine and climbazole and its combination with a tonic reduced dandruff and inflammation, with the combination showing superior results.

This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.

In this case report, a 47-year-old man with extensive psoriasis saw significant improvement in scaling and itching after using a new lotion containing clobetasol and other ingredients for one week, but further research is needed to confirm these findings.

This review concluded that Diphenylcyclopropenone may offer the best treatment results for alopecia areata, although further research into the disease's pathogenesis could improve therapeutic options.